Palisade Bio Stock Surges on Positive FDA Clearance for Next-Gen IBD Therapy

The FDA has cleared Palisade Bio’s investigational new drug application for PALI-2108. The company will now start its Phase 2 ASCENTRA-UC trial in H2 2026.